Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antisense
Biotech
Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks
Eight of the 11 patients on the high dose were attack free through to the latest follow up, which tracked patients for a median of eight months.
Nick Paul Taylor
Oct 24, 2024 8:55am
Takeda axes Huntington’s pact, freeing Wave to pursue partners
Oct 16, 2024 8:07am
Denali reports new method to get ASOs across blood-brain barrier
Aug 14, 2024 2:00pm
Ionis axes eye disease from targets of Roche-partnered prospect
Aug 1, 2024 8:06am
Lilly pays QurAlis $45M for preclinical ALS, dementia prospect
Jun 3, 2024 5:00am
Novo Nordisk inks $1B buyout to pump up heart failure plans
Mar 25, 2024 7:20am
